Infex to present RESP-X Phase I data at ERS Congress

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that Phase I data from RESP-X, the Company’s first-in-class anti-virulence antibody, will be presented in an oral presentation by Colm Leonard, Chief Clinical Officer at Infex, at the 2024 European Respiratory Society (ERS) Congress, held in Vienna, Austria from 7-11 September 2024.

RESP-X is a phase II, first-in-class anti-virulence antibody, targeting chronic Pseudomonas aeruginosa (Pa) bacterial infections in respiratory diseases. RESP-X is initially being developed as a long-term preventative treatment for Non-Cystic Fibrosis Bronchiectasis (NCFB) patients colonised with Pseudomonas aeruginosa, a chronic and debilitating respiratory disease, with potential to expand into cystic fibrosis and COPD in addition to acute settings such as hospital and ventilator-acquired pneumonia and blood stream infections due to Pa. Colonisation with Pa increases the severity of NCFB, leading to recurring episodes of debilitating and life-threatening infection. There are currently up to six million NCFB patients in major global markets, of which up to 30% have chronic Pa colonisation. Despite its prevalence and severity, there are currently no licensed treatments for the prevention of infective exacerbations due to Pa colonisation in NCFB patients.

RESP-X blocks Pa exotoxin delivery by the Pa type III secretion system (T3SS). The T3SS is a critical mechanism by which Pa causes organ injury, evades the immune system and gains a foothold in humans. By blocking this virulence system RESP-X downgrades the ability of Pa to attack human tissues and restores the ability of immune cells to control Pa. Phase I data showed RESP-X was safe in healthy volunteers, with no serious or adverse events (“SAEs”) or infusion reactions reported. Therefore, INFEX are currently recruiting patients for the phase 2a study in NCFB patients in NW England and plans for the phase 2b study of RESP-X- in NCFB patients to reduce the frequency and severity of exacerbations are well advanced.

The ERS Congress is an annual event that brings together the world’s respiratory experts to showcase all the latest advances in respiratory medicine and science.

Details of the presentation are as follows:

A copy of the presentation will be made available on the Company’s website following the presentation at: https://www.infextx.com/publications/